Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza® from Acorda Therapeutics, Inc. Grünenthal is now the sole owner of Qutenza® worldwide, including the US, Latin America, Asia and Australia. Grünenthal had already acquired exclusive commercial rights for Europe, Middle East and Africa in December 2016.
“As a leader in pain research and management, we’re dedicated to providing solutions for patients with high unmet medical needs. Qutenza® is a perfect strategic fit, as it complements our existing pain portfolio and is a real alternative to the current standard of care,” says Gabriel Baertschi, Grünenthal’s Chief Executive Officer.
Qutenza® is a highly effective pain product. A single, 1-hour, localised treatment with this patch may provide at least 3 months of relief from for example post-shingles nerve pain. Grünenthal will aim to make Qutenza ® available to patients worldwide. In territories where the company does not have a presence of its own such as Asia and Australia, Grünenthal will look to partner or out-license Qutenza®.
Grünenthal continues executing its growth strategy and has been expanding its pain portfolio by a series of acquisitions including European rights to Nexium®, the global (ex US and Japan) rights to Vimovo® and global (ex Japan) rights to Zomig®. The company has signed deals with a total value of more than US$ 1.3 billion since 2016.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: November 12, 2018
Source: Cision